Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer [PDF]
Genetics; Metastasis; ProstateGenética; Metástasis; PróstataGenètica; Metàstasi; PròstataWhat is this summary about?: This summary describes the results from the TALAPRO-2 research study (also known as a clinical trial).
Agarwal, Neeraj +5 more
core +1 more source
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers [PDF]
, 2017 Talazoparib inhibits PARP catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this two-part, phase I, first-in-human trial.
Byers, Lauren Averett +15 more
core +1 more source
The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease [PDF]
, 2016 Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second “European interdisciplinary Ewing sarcoma research summit” assembled a large group of scientific experts in the field to discuss their latest ...
Amatruda, James +5 more
core
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial [PDF]
Talazoparib; Cáncer de próstata metastásico resistente a la castraciónTalazoparib; Metastatic castration-resistant prostate cancerTalazoparib; Càncer de pròstata metastàtic resistent a la castracióPreclinical evidence has suggested an interplay between ...
Azad, Arun +5 more
core +1 more source
eBioMedicineLoss of heterozygosity (LOH) diminishes genetic diversity within cancer genomes. A tumour arising in an individual heterozygous for a functional and a loss-of-function (LoF) allele of a gene occasionally retain only the LoF allele. This can result in deficiency of specific protein activities in cancer cells, creating unique differences between tumour ...
Xiaonan Zhang +18 more
openaire +5 more sources
Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors
CancersMalignant rhabdoid tumors (MRTs) are among the most aggressive and treatment-resistant malignancies affecting infants, originating in the kidney, brain, liver, and soft tissues. The 5-year event-free survival rate for these cancers is a mere 20%. In nearly all cases of MRT, the SMARCB1 gene (occasionally SMARCA4)—a pivotal component of the SWI/SNF ...
Elena Mironova +9 more
openaire +2 more sources
ROLE OF c-MET and EGFR IN ACQUIRED RESISTANCE TO PARP INHIBITORS IN TRIPLE-NEGATIVE BREAST CANCER [PDF]
, 2019 Triple-negative breast cancer is associated with a poor prognosis and treatment options are limited. The Poly (ADP-ribose) polymerase (PARP) inhibitors, olaparib and talazoparib, were recently approved for metastatic breast cancer (including triple ...
Yam, Clinton
core +1 more source
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [PDF]
inhibitors; Prostatic neoplasmsInhibidors; Neoplàsies prostàtiquesInhibidores; Neoplasias prostáticasBackground This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-
Azad, Arun +6 more
core +1 more source
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer [PDF]
Importance: Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration–approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most ...
Bouberhan, Sara +23 more
core +1 more source